Breast Cancer

BREAST CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life

Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Conference Organizers Can Help Oncologists Distill Practice-Changing Data

A SABCS 2019 session encouraged oncologists to scrutinize whether presentations are practice changing, and included a look at controversial data from KEYNOTE-522.
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing

The cancer field is not immune to the challenges of out-of-network and surprise billing.
Oncotype DX Shown to Work Differently in Men and Women With Breast Cancer

The tool is still diagnostically useful in both cases, it just may require sex-specific guidelines for use.
The FDA Approval Process Needs Refinement, Not a Total Overhaul

Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.

VIDEO SERIES

The Phase 3 PlanB Trial

Continue to Work?

Drug Resistance to CDK4/6 Inhibitors

Comparing Ribociclib and Palbociclib

Ribociclib, Abemaciclib, and Palbociclib

The Potential of CDK4/6 Inhibitors

How Cyclin D Plays A Role

2016 SABCS: Clinical Insights Telli

2016 SABCS: Clinical Insights Oregan

HER2-positive Metastatic and TNBC

Frontline Treatments

Treatment-related Neuropathy

ER-positive, HER2-negative

Emerging Medicines

Triple-negative Breast Cancer

Insights from the Lab and Clinic

Trastuzumab Resistance

Biologic Role of HER2

Strategies in Management

BREAST CANCER NEWS

While women who lost more than 5 kg after age 18 were at a 23% reduced risk for breast cancer, those

High BMI May Cut Overall Survival in HER2+ Metastatic Breast Cancer

February 13, 2020

Addition of bevacizumab to NCCN guidelines as a frontline therapy in ovarian cancer spurred more utilization of the drug than did fresh findings from clinical trials.

CMS Covers Next-Generation Sequencing for Breast and Ovarian Cancer

February 7, 2020

Emerging Therapeutic Approaches for Metastatic HER2-Positive Breast Cancer

January 31, 2020

Preventive treatments are strongly recommended in women with AH and LCIS.

Updated Guidelines Issued for ER, PgR Testing in Breast Cancer

January 28, 2020

The ASCO/CAP Expert Panel continues to recommend IHC as the only primary screening test for predicting benefit of endocrine therapy in breast cancer.

Update to ASCO/CAP Guideline in Breast Cancer: No Sweeping Changes, but Many Refinements

January 21, 2020

Next post in Breast Cancer

A SABCS 2019 session encouraged oncologists to scrutinize whether presentations are practice changing, and included a look at controversial data from KEYNOTE-522.

Conference Organizers Can Help Oncologists Distill Practice-Changing Data